Cas:1217024-56-0 morpholine-13C4 manufacturer & supplier

Chemical Name:morpholine-13C4

CAS.NO:1217024-56-0

Synonyms:[13C4]-Morpholine;Drewamine-13C4;1-Oxa-4-azacyclohexane-13C4;Diethylenimide Oxide-13C4;2H-1,4-Oxazine,tetrahydro;Morpholine-13C4

Molecular Formula:C₄H₉NO

Molecular Weight:91.09100

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:21.26000

Exact Mass:91.08180

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like [13C4]-Morpholine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Morpholine-13C4 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2H-1,4-Oxazine,tetrahydro Use and application,[13C4]-Morpholine technical grade,usp/ep/jp grade.

Related News: If the results from that trial are positive, the company might apply to the U.S. Food and Drug Administration for the same accelerated approval pathway recently used to bring the controversial Alzheimer’s drug aducanumab to market, Novak said. morpholine-13C4 manufacturer The API is not made by only one reaction from the raw materials but rather it becomes an API via several chemical compounds. morpholine-13C4 supplier If the results from that trial are positive, the company might apply to the U.S. Food and Drug Administration for the same accelerated approval pathway recently used to bring the controversial Alzheimer’s drug aducanumab to market, Novak said. morpholine-13C4 vendor If the results from that trial are positive, the company might apply to the U.S. Food and Drug Administration for the same accelerated approval pathway recently used to bring the controversial Alzheimer’s drug aducanumab to market, Novak said. morpholine-13C4 factory What’s more, also at the EHA meeting, BeiGene’s Brukinsa showed it could outperform Imbruvica at triggering tumor responses while causing fewer cases of atrial fibrillation, a potentially dangerous heart side effect, in its own head-to-head phase 3 study in previously treated CLL.